The ROSA Shoulder robotic application has received positive feedback, indicating strong potential for long-term growth in the robotics-assisted surgery segment. Additionally, Zimmer Biomet has ...

Gross margins are projected to range from 47% to 51%, benefiting from improved transfer pricing under the Zimmer Biomet partnership. Rosa stated that the company is on track to submit a 510(k ...

Zimmer Biomet (NYSE: ZBH) announced today that it received FDA 510(k) clearance for its Persona Revision SoluTion Femur.

Zimmer Biomet is updating its board of directors, naming a new chair and lead independent director, according to a Feb. 26 news release.

SINGAPORE, March 30, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that ROSA HIP ® with ONE Plannerâ„¢ Hip won the ...

Zimmer Biomet posted fourth-quarter revenue growth of 5% in constant currency, which is generally consistent with the preceding quarters in 2024. Why it matters: As Zimmer Biomet has pursued a ...

WARSAW, Ind., Feb. 25, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced upcoming changes to the Company's Board of ...

WARSAW, Ind., March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA ...

Zimmer Biomet's product pipeline remains a key strength, with several innovative offerings poised to drive future growth. The ROSA Shoulder robotic application has received positive feedback ...